Accelerated neurodegeneration through chaperone-mediated oligomerization of tau
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Aggregation of tau protein in the brain is associated with a class of neurodegenerative diseases known as tauopathies. FK506 binding protein 51 kDa (FKBP51, encoded by FKBP5) forms a mature chaperone complex with Hsp90 that prevents tau degradation. In this study, we have shown that tau levels are reduced throughout the brains of Fkbp5-/- mice. Recombinant FKBP51 and Hsp90 synergized to block tau clearance through the proteasome, resulting in tau oligomerization. Overexpression of FKBP51 in a tau transgenic mouse model revealed that FKBP51 preserved the species of tau that have been linked to Alzheimer's disease (AD) pathogenesis, blocked amyloid formation, and decreased tangle load in the brain. Alterations in tau turnover and aggregate structure corresponded with enhanced neurotoxicity in mice. In human brains, FKBP51 levels increased relative to age and AD, corresponding with demethylation of the regulatory regions in the FKBP5 gene. We also found that higher FKBP51 levels were associated with AD progression. Our data support a model in which age-associated increases in FKBP51 levels and its interaction with Hsp90 promote neurotoxic tau accumulation. Strategies aimed at attenuating FKBP51 levels or its interaction with Hsp90 have the potential to be therapeutically relevant for AD and other tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hsp90:FKBP51 functions in tau proteostasis, increasing its stability and altering phosphorylation states”
From The structure of an Hsp90-immunophilin complex reveals cochaperone recognition of the client maturation state (2021) · cites this paper as Blair et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“since FKBP5 site-specific demethylation occurs with age (49).”
From Holocaust Exposure Induced Intergenerational Effects on FKBP5 Methylation (2016) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Introduction Neurofibrillary tangles, hallmarks of a class of neurodegenerative diseases termed tauopathies, are comprised of microtubule-associated tau protein aggregates that persist in the brain even after neuron death (1).”
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES
Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,487 · cited 2×
“3- to 4-times more abundant in cells than 26S proteasomes (35).”
Whitmore, L., & Wallace, B. A. (2008) · Biopolymers · doi:10.1002/bip.20853 · Cited by 2,243
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · cited 1×
“This same model displays cognitive recovery when tau is suppressed, despite continued tangle formation (5, 46).”
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
The Amyloid State of Proteins in Human Diseases
Eisenberg, D., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,744
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“However, levels of neuronal death in AD far exceed what is expected based on the observed numbers of tau tangles (2), suggesting that a different mechanism is primarily responsible for neurodegeneration.”
Cited by
Holocaust Exposure Induced Intergenerational Effects on FKBP5 Methylation
Yehuda, R., Daskalakis, N. P., Bierer, L. M., Bader, H. N., Klengel, T., Holsboer, F., & Binder, E. B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.005 · Cited by 782
“F1: 45 years), which could explain their 12% methylation difference at bin 3/site 6, since FKBP5 site-specific demethylation occurs with age (49).”
BackgroundSelf-citationThe role of protein clearance mechanisms in organismal ageing and age-related diseases
Vilchez, D., Saez, I., & Dillin, A. (2014) · Nature Communications · doi:10.1038/ncomms6659 · Cited by 689
Gene–Stress–Epigenetic regulation of FKBP5: clinical and translational implications
Zannas, A. S., Wiechmann, T., Gassen, N. C., & Binder, E. B. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.235 · Cited by 622
“More recently, postmortem studies have found FKBP5 overexpression in several brain regions in association with Alzheimer’s disease and schizophrenia (Blair et al, 2013; Sinclair et al, 2013).”
BackgroundSelf-citationTau Protein Modifications and Interactions: Their Role in Function and Dysfunction
Mietelska-Porowska, A., Wasik, U., Goras, M., Filipek, A., & Niewiadomska, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034671 · Cited by 404
“dephosphorylation [192] and its overexpression enhanced neuronal loss in the rTg4510 tau transgenic mouse model [196].”
BackgroundThe Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
Lackie, R. E., Maciejewski, A., Ostapchenko, V. G., Marques-Lopes, J., Choy, W.-Y., Duennwald, M. L., Prado, V. F., & Prado, M. A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00254 · Cited by 374
“Dickey and colleagues also found that FKBP51 expression is increased with age and in AD (Blair et al., 2013).”
BackgroundZannas, A. S., Jia, M., Hafner, K., Baumert, J., Wiechmann, T., Pape, J. C., Arloth, J., Ködel, M., Martinelli, S., Roitman, M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816847116 · Cited by 352
“Interestingly, FKBP5 up-regulation has been observed not only with stress exposure and glucocorticoid stimulation but also in the aging brain (20, 21) and in some disease phenotypes (15, 17, 20).”
Self-citationHsp90-Tau complex reveals molecular basis for specificity in chaperone action
Karagöz, G. E., Duarte, A. M. S., Akoury, E., Ippel, H., Biernat, J., Morán Luengo, T., Radli, M., Didenko, T., Nordhues, B. A., Veprintsev, D. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.037 · Cited by 318
“As recently described, Hsp90 and the cochaperone FKBP51 can prevent Tau from forming dense amyloids and rather promote the formation of more toxic Tau intermediates (Blair et al., 2013).”
BackgroundSelf-citationThe Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Saez, I., & Vilchez, D. (2014) · Current Genomics · doi:10.2174/138920291501140306113344 · Cited by 325
“In mice, FKBP51 and HSP90 synergize to block tau clearance by the proteasome, resulting in tau oligomerization [127].”
BackgroundXu, M., Zhang, D., Luo, R., Wu, Y., Zhou, H., Kong, L., Bi, R., & Yao, Y. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.012 · Cited by 296
“By January 2016, a total of 20 expression datasets were obtained: GSE12685 [1], GSE48350 [2], GSE66333 [3], GSE53890 [4], GSE36980 [5], GSE13214 [6], GSE15222 [7], GSE5281 [8, 9], GSE44770 [10], GSE33000 [11], GSE9770 [12], GSE37264 (exon level) [13], GSE37263 (gene level) [14], GSE29652 [15], GSE28146 [16], GSE1297 […”
BackgroundCastillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278
“, tau oligomeric intermediates) in tauopathies is poorly understood; however, novel polyclonal and monoclonal antibodies that define specific tau species have enabled the study of tau oligomers in vivo (Patterson et al., 2011; Lasagna-Reeves et al., 2012a; Blair et al., 2013; Hawkins et al., 2013; Wu et al., 2013).”
BackgroundSelf-citationRole of tau protein in Alzheimer’s disease: The prime pathological player
Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278
Gene–environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism
Zannas, A. S., & Binder, E. B. (2014) · Genes, Brain and Behavior · doi:10.1111/gbb.12104 · Cited by 268
“Interestingly, FKBP5 expression has been shown to increase with age in the postcentral gyrus, entorhinal cortex, superior-frontal gyrus and hippocampus of the human brain (Blair et al. 2013).”
BackgroundSelf-citationMatosin, N., Halldorsdottir, T., & Binder, E. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.021 · Cited by 226
Self-citationTau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220
Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy
Blair, L. J., Frauen, H. D., Zhang, B., Nordhues, B. A., Bijan, S., Lin, Y.-C., Zamudio, F., Hernandez, L. D., Sabbagh, J. J., Selenica, M.-L. B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0186-2 · Cited by 193
“5 months of age, roughly 80% of neurons in the CA1 and dentate gyrus are lost [22,24-27].”
BackgroundSelf-citationArgentieri, M. A., Nagarajan, S., Seddighzadeh, B., Baccarelli, A. A., & Shields, A. E. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.044 · Cited by 188
“One study examiningmedial temporal gyrus brain tissue from 15 elderly U.S. adults found that one CpG site in intron 7 and two CpGs in the promoter of FKBP5 showed significant hypomethylation in Alzheimer's disease (AD) cases versus healthy controls (Blair et al., 2013).”
BackgroundCastillo-Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., & Kayed, R. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132477 · Cited by 182
Self-citationProteostasis collapse is a driver of cell aging and death
Santra, M., Dill, K. A., & de Graff, A. M. R. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906592116 · Cited by 175
“Although there are apparent exceptions, such as the acceleration of neurodegeneration upon overexpression of HSP90 in mice (82), it should be noted that HSP90 can be a negative regulator of the HSP70 chaperones studied here.”
Lang, B. J., Guerrero, M. E., Prince, T. L., Okusha, Y., Bonorino, C., & Calderwood, S. K. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03070-8 · Cited by 162
“Chaperones may, therefore, play differing roles in protein folding disorders as illustrated by the findings that Hsp90 may facilitate some of the pathophysiological events occurring in tauopathies by stabilizing disease related aggregates (Luo et al. 2007; Blair et al. 2013).”
BackgroundSmall Heat Shock Proteins, Big Impact on Protein Aggregation in Neurodegenerative Disease
Webster, J. M., Darling, A. L., Uversky, V. N., & Blair, L. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01047 · Cited by 160
Self-citationHypothalamic-Pituitary-Adrenal Axis Dysfunction and Illness Progression in Bipolar Disorder
Fries, G. R., Vasconcelos-Moreno, M. P., Gubert, C., Santos, B. T. M. Q. D., Sartori, J., Eisele, B., Ferrari, P., Fijtman, A., Ruegg, J., Gassen, N. C., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu043 · Cited by 147
“FKBP5 methylation was analyzed by bisulfite pyrosequencing, as previously described (Blair et al., 2013; Klengel et al., 2013).”
MethodФедотчева, Т. А., Fedotcheva, N. I., & Shimanovsky, N. L. (2022) · Biomolecules · doi:10.3390/biom12091299 · Cited by 157
Paquette, A. G., Lester, B. M., Koestler, D. C., Lesseur, C., Armstrong, D. A., & Marsit, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104913 · Cited by 130
“FKBP5 methylation within a regulatory region of intron 7 has been associated with neurological outcomes [19,20].”
BackgroundHsp90 activator Aha1 drives production of pathological tau aggregates
Shelton, L. B., Baker, J. D., Zheng, D., Sullivan, L. E., Solanki, P. K., Webster, J. M., Sun, Z., Sabbagh, J. J., Nordhues, B. A., Koren, J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707039114 · Cited by 128
“Human tissue was stained as previously described using immunofluorescent secondary antibodies (17, 37).”
BackgroundMethodSelf-citationGassen, N. C., Chrousos, G. P., Binder, E. B., & Zannas, A. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.003 · Cited by 139
Self-citationBlair, L. J., Baker, J. D., Sabbagh, J. J., & Dickey, C. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13033 · Cited by 120
Self-citationHsp90 and Its Co-Chaperones in Neurodegenerative Diseases
Bohush, A., Bieganowski, P., & Filipek, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20204976 · Cited by 133
“One study identifies FKBP51, unlike other co-chaperones, to be significantly up-regulated in aged and AD brains [56].”
BackgroundGunawardana, C. G., Mehrabian, M., Wang, X., Mueller, I., Lubambo, I. B., Jonkman, J. E. N., Wang, H., & Schmitt-Ulms, G. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.050724 · Cited by 130
“Although one of the previously proposed FKBP family members to interact with tau (30, 31), namely FKBP5 (otherwise known as FKBP51), was also detected in this study, its level of tau co-isolation was lower than for FKBP3.”
BackgroundWang, P., Joberty, G., Buist, A., Vanoosthuyse, A., Stancu, I.-C., Vasconcelos, B., Pierrot, N., Faelth-Savitski, M., Kienlen-Campard, P., Octave, J.-N., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1663-9 · Cited by 117
“Along the same vein, molecular chaperon FKBP51, together with Hsp90, increase Tau oligomer formation by inhibiting Tau degradation through the proteasome in a mouse model [8].”
BackgroundTargeting Hsp90 and its co-chaperones to treat Alzheimer’s disease
Blair, L. J., Sabbagh, J. J., & Dickey, C. A. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.943185 · Cited by 117
“In a more recent study, FKBP52 was found to interact with tau to produce tau oligomers [101], similar to the results we demonstrated with FKBP51 and tau [17].”
BackgroundResultSelf-citationThe dendritic hypothesis for Alzheimer's disease pathophysiology
Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114
Tau Protein Squired by Molecular Chaperones During Alzheimer’s Disease
Gorantla, N. V., & Chinnathambi, S. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1174-3 · Cited by 119
Shemesh, N., Jubran, J., Dror, S., Simonovsky, E., Basha, O., Argov, C. M., Hekselman, I., Abu‐Qarn, M., Vinogradov, E., Mauer, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22369-9 · Cited by 119
“Whereas chaperone overexpression typically improves the folding capacity of the chaperone system, overexpression of specific chaperones was shown to disrupt folding (19-22).”
BackgroundSelective targeting of the stress chaperome as a therapeutic strategy
Taldone, T., Ochiana, S. O., Patel, P. D., & Chiosis, G. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.001 · Cited by 111
Molecular Chaperones: A Double-Edged Sword in Neurodegenerative Diseases
Tittelmeier, J., Nachman, E., & Nussbaum-Krammer, C. I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.581374 · Cited by 118
Structure and pro-toxic mechanism of the human Hsp90/PPIase/Tau complex
Oroz, J., Chang, B. J., Wysoczanski, P., Lee, C.-T., Pérez-Lara, Á., Chakraborty, P., Hofele, R. V., Baker, J. D., Blair, L. J., Biernat, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06880-0 · Cited by 100
Self-citationChopra, N., Wang, R., Maloney, B., Nho, K., Beck, J. S., Pourshafie, N., Niculescu, A., Saykin, A. J., Rinaldi, C., Counts, S. E., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0610-2 · Cited by 101
Age-Associated Epigenetic Upregulation of the FKBP5 Gene Selectively Impairs Stress Resiliency
Sabbagh, J. J., O'Leary, J. C., Blair, L. J., Klengel, T., Nordhues, B. A., Fontaine, S. N., Binder, E. B., & Dickey, C. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107241 · Cited by 101
“While demethylation of FKBP5 has been identified as a potential mechanism for FKBP51 upregulation in humans [7,12], it was not known if this was contributing to the progressive increases in FKBP51 that we observed in aged mice [8].”
BackgroundMethodInfluentialSelf-citationAnnett, S., Moore, G., & Robson, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107623 · Cited by 111
study, T. A. I. B. A. L., Nabais, M. F., Initiative, T. A. D. N., Laws, S. M., Lin, T., Vallerga, C. L., Armstrong, N. J., Blair, I. P., Kwok, J. B., Mather, K. A., et al. (2021) · Genome Biology · doi:10.1186/s13059-021-02275-5 · Cited by 99
The mechanism of Hsp90-induced oligomerizaton of Tau
Weickert, S., Wawrzyniuk, M., John, L., Rüdiger, S., & Drescher, M. (2020) · Science Advances · doi:10.1126/sciadv.aax6999 · Cited by 102
Chaperones in Neurodegeneration
Lindberg, I., Shorter, J., Wiseman, R. L., Chiti, F., Dickey, C. A., & McLean, P. J. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2600-15.2015 · Cited by 93
“Interestingly, Hsp90 and a recently identified cochaperone, the cis-/trans peptidyl-prolyl isomerase (PPIase) FK506 binding protein 51 (FKBP51), coordinate to provoke tau pathogenesis by reducing tau -sheet amyloidosis (Blair et al., 2013).”
BackgroundMethodSelf-citationThe Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer’s Disease
Sulistio, Y. A., & Heese, K. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-9063-4 · Cited by 98
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Parsi, S., Smith, P. Y., Goupil, C., Dorval, V., & Hébert, S. S. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.33 · Cited by 83
Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD
Hedl, T. J., San Gil, R., Cheng, F., Rayner, S. L., Davidson, J. M., De Luca, A., Villalva, M. D., Ecroyd, H., Walker, A. K., & Lee, A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00548 · Cited by 87
Bioinformatics methods in drug repurposing for Alzheimer’s disease
Siavelis, J. C., Bourdakou, M. M., Athanasiadis, E. I., Spyrou, G. M., & Nikita, K. S. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv048 · Cited by 87
Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 85
“with Hsp90 promoting neurotoxic NFT accumulation [686]”
Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies
Shelton, L. B., Koren, J., & Blair, L. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00724 · Cited by 84
“Taken together, increased FKBP51 and decreased PP5 and CyP40 could contribute to an imbalance in Hsp90 heterocomplexes which may promote increased tau phosphorylation and aggregation causing neurotoxicity (Blair et al., 2013).”
BackgroundInfluentialSelf-citationCao, M., Li, H., Zhao, J., Cui, J., & Hu, G. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.023 · Cited by 79
DNA methylation dynamics in plants and mammals: overview of regulation and dysregulation
Elhamamsy, A. R. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3183 · Cited by 87
“The decrease of DNA methylation in FKBP51 increased its expression and high level of FKBP51 protein were associated with AD progression.(85) HD is a hereditary neurodegenerative disorder manifested generally after mid-30s.”
BackgroundLee, K., Thwin, A. C., Nadel, C. M., Tse, E., Gates, S. N., Gestwicki, J. E., & Southworth, D. R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.023 · Cited by 76
Das, R. C., Rauf, A., Akhter, S., Islam, M. N., Emran, T. B., Mitra, S., Khan, I. N., & Mubarak, M. S. (2021) · Molecules · doi:10.3390/molecules26123696 · Cited by 83
“Furthermore, Hsp90 accelerates aberrant accumulation and aggregation of τ protein [126] and induces Aβ toxicity in AD [126].”
BackgroundDiverse structures, functions and uses of FK506 binding proteins
Bonner, J. M., & Boulianne, G. L. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.06.013 · Cited by 82
Baker, J. D., McMillan, I. O., Ospina, S. R., Gulick, D., & Blair, L. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010079 · Cited by 79
“Since FKBP51 works in a short, negative feedback loop with GR, increased FKBP51 levels may directly regulate the activation of the negative feedback loop of the clock FKBP51 levels can be affected not only by SNPs, but they also dramatically increase with age [102,103].”
BackgroundSelf-citationGerson, J. E., Castillo-Carranza, D. L., & Kayed, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500143n · Cited by 72
Self-citationBhattacharya, K., & Picard, D. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03962-z · Cited by 81
Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels
Bailus, B. J., Scheeler, S. M., Simons, J., Sanchez, M. A., Tshilenge, K., Creus‐Muncunill, J., Naphade, S. B., Lopez‐Ramirez, A., Zhang, N., Madushani, K. L., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1904489 · Cited by 78
“FKBP4 binds to MAPT/tau (microtubule associated protein tau), regulating its function and degradation, and FKBP5 prevents MAPT degradation and enhances neurotoxicity [27,32].”
BackgroundUbiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23
Blount, J. R., Tsou, W., Ristic, G., Burr, A. A., Ouyang, M., Galante, H., Scaglione, K. M., & Todi, S. V. (2014) · Nature Communications · doi:10.1038/ncomms5638 · Cited by 76
Self-citationEpigenetics as a key link between psychosocial stress and aging: concepts, evidence, mechanisms
Zannas, A. S. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.4/azannas · Cited by 79
Lo, C. H., Lim, C. K., Ding, Z., Wickramasinghe, S. P., Braun, A. R., Ashe, K. H., Rhoades, E., Thomas, D. D., & Sachs, J. N. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4954 · Cited by 67
Sinnige, T., Yu, A., & Morimoto, R. I. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-40204-4_4 · Cited by 65
Violet, M., Chauderlier, A., Delattre, L., Tardivel, M., Chouala, M. S., Sultan, A., Marciniak, E., Humez, S., Binder, L., Kayed, R., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.003 · Cited by 66
Self-citationCell-type-specific effects of age and sex on human cortical neurons
Chien, J.-F., Liu, H., Wang, B.-A., Luo, C., Bartlett, A., Castanon, R., Johnson, N. D., Nery, J. R., Osteen, J. K., Li, J., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.013 · Cited by 74
Zafeiris, D., Rutella, S., & Ball, G. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.02.001 · Cited by 72
“The dataset used for this experiment is [dataset] E-GEOD-48350 [35].”
BackgroundMethodMaiarù, M., Morgan, O. B., Mao, T., Breitsamer, M., Bamber, H., Pöhlmann, M., Schmidt, M. V., Winter, G., Hausch, F., & Géranton, S. M. (2018) · Pain · doi:10.1097/j.pain.0000000000001204 · Cited by 62
“We had previously reported than FKBP51 was mainly expressed in neurons of the superficial dorsal horn of mice and rats that were naïve or had an inflamed joint [15,21] and this was supported by others [6].”
S-Nitrosylation in Alzheimer's disease
Zhao, Q., Yu, J., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8672-2 · Cited by 67
“Additionally, HSP90 can work with another chaperone, FK506-binding protein51 (FKBP51), to alter tau structure, block tau degradation, and promote abnormal oligomer formation, thus preventing tau clearance and facilitating its neurotoxicity [86].”
Human cyclophilin 40 unravels neurotoxic amyloids
Baker, J. D., Shelton, L. B., Zheng, D., Favretto, F., Nordhues, B. A., Darling, A., Sullivan, L. E., Sun, Z., Solanki, P. K., Martin, M. D., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001336 · Cited by 62
Self-citationKim, S., Kim, D. K., Jeong, S., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115894 · Cited by 75
Zheng, D., Sabbagh, J. J., Blair, L. J., Darling, A. L., Wen, X., & Dickey, C. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.727941 · Cited by 61
“Previous studies have demonstrated that FKBP5 expression increases with age in humans (11).”
InfluentialSelf-citationCellular factors modulating the mechanism of tau protein aggregation
Fontaine, S. N., Sabbagh, J. J., Baker, J., Martinez-Licha, C. R., Darling, A., & Dickey, C. A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1839-9 · Cited by 60
Self-citationArginine π-stacking drives binding to fibrils of the Alzheimer protein Tau
Ferrari, L., Stucchi, R., Konstantoulea, K., van de Kamp, G., Kos, R., Geerts, W. J. C., van Bezouwen, L. S., Förster, F. G., Altelaar, M. A. F., Hoogenraad, C. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13745-7 · Cited by 67
Matosin, N., Arloth, J., Czamara, D., Edmond, K. Z., Maitra, M., Fröhlich, A. S., Martinelli, S., Kaul, D., Bartlett, R., Curry, A. R., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02541-9 · Cited by 61
Self-citationBehind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity
Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 59
“Interestingly, NFTs did not excessively form under FKB51 elevation, suggesting that other aggregated tau forms contributed more to the toxicity [209].”
Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer’s disease
Silva, T. C., Young, J. I., Zhang, L., Gomez, L., Schmidt, M. A., Varma, A., Chen, X. S., Martin, E. R., & Wang, L. (2022) · Nature Communications · doi:10.1038/s41467-022-32475-x · Cited by 62
Self-citationMalekpour, M., Shekouh, D., Safavinia, M. E., Shiralipour, S., Jalouli, M., Mortezanejad, S., Azarpira, N., & Ebrahimi, N. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1182345 · Cited by 85
“Thus, changes in FKBP51 expression and function are associated with the occurrence of a wide variety of disorders, including metabolic syndrome (65), Alzheimer’s disease (66), the development of different types of cancer, cardiovascular disease, and immune disturbances, in addition to stress-induced psychiatric disord…”
BackgroundSilva, T. C., Young, J. I., Zhang, L., Gomez, L., Schmidt, M. A., Varma, A., Chen, X. S., Martin, E. R., & Wang, L. (2022) · doi:10.1101/2022.04.11.22273748 · Cited by 57
Self-citationCo-expression of truncated and full-length tau induces severe neurotoxicity
Ozcelik, S., Sprenger, F., Skachokova, Z., Fraser, G., Abramowski, D., Clavaguera, F., Probst, A., Frank, S., Müller, M., Staufenbiel, M., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.228 · Cited by 55
Female-specific effect of the BDNF gene on Alzheimer's disease
Li, G.-D., Bi, R., Zhang, D., Xu, M., Luo, R., Wang, D., Fang, Y., Li, T., Zhang, C., & Yao, Y. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.12.023 · Cited by 58
Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy
Hunt, J. B., Nash, K. R., Placides, D., Moran, P., Selenica, M.-L. B., Abuqalbeen, F., Ratnasamy, K., Slouha, N., Rodriguez-Ospina, S., Savlia, M., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3959-14.2015 · Cited by 53
Self-citationKishinevsky, S., Wang, T., Rodina, A., Chung, S. Y., Xu, C., Philip, J., Taldone, T., Joshi, S., Alpaugh, M. L., Bolaender, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06486-6 · Cited by 57
Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice
Criado-Marrero, M., Gebru, N. T., Blazier, D. M., Gould, L. A., Baker, J. D., Beaulieu-Abdelahad, D., & Blair, L. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01159-w · Cited by 46
“Specific actions on tau protein will depend on the association of Hsp90 with many other chaperones forming a heterocomplex [11, 18, 19, 74, 90].”
BackgroundMethodInfluentialSelf-citationNitric Oxide Homeostasis in Neurodegenerative Diseases
Hannibal, L. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921101250 · Cited by 57
Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma
Stothert, A. R., Suntharalingam, A., Huard, D. J. E., Fontaine, S. N., Crowley, V. M., Mishra, S., Blagg, B. S. J., Lieberman, R. L., & Dickey, C. A. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu367 · Cited by 49
“This is not the first time that an Hsp90 protein was shown to accelerate the aggregation of an amyloid-prone protein: Hsp90awas previously shown to stimulate the aggregation of tau (29).”
BackgroundSelf-citationYu, S., Yu, M., Bu, Z., He, P., & Feng, J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00193 · Cited by 51
“Increased FKBP5 has been detected for stress and glucocorticoid-stimulated conditions in the aging brain (Blair et al., 2013).”
BackgroundFröhlich, A. S., Gerstner, N., Gagliardi, M., Ködel, M., Yusupov, N., Matosin, N., Czamara, D., Sauer, S., Roeh, S., Murek, V., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01742-z · Cited by 66
“Single-nucleotide polymorphisms (SNPs) in FKBP5 are associated with an increased risk for several psychiatric disorders, and FKBP5 has been implicated in Alzheimer’s disease (AD) by interfering with tau processing 23,24 .”
BackgroundSelf-citationBlair, L. J., Criado-Marrero, M., Zheng, D., Wang, X., Kamath, S., Nordhues, B. A., Weeber, E. J., & Dickey, C. A. (2019) · eneuro · doi:10.1523/eneuro.0242-18.2019 · Cited by 49
“Moreover, FKBP5 expression progressively increases with normal aging, concomitant with reduced FKBP5 DNA methylation, and has been associated with the number one cause of dementia in the world, Alzheimer’s disease (Jinwal et al., 2010; Blair et al., 2013; Sabbagh et al., 2014).”
BackgroundSelf-citationChaperones—A New Class of Potential Therapeutic Targets in Alzheimer’s Disease
Batko, J., Antosz, K., Miśków, W., Pszczołowska, M., Walczak, K., & Leszek, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063401 · Cited by 51
Sabbagh, J. J., Cordova, R. A., Zheng, D., Criado-Marrero, M., Lemus, A., Li, P., Baker, J. D., Nordhues, B. A., Darling, A. L., Martinez-Licha, C., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00454 · Cited by 48
Self-citationEnhanced tau pathology via RanBP9 and Hsp90/Hsc70 chaperone complexes
Woo, J. A., Liu, T., Zhao, X., Trotter, C., Yrigoin, K., Cazzaro, S., Narvaez, E. D., Khan, H., Witas, R., Bukhari, A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx284 · Cited by 46
Self-citationAdvances towards Understanding the Mechanism of Action of the Hsp90 Complex
Prodromou, C., & Bjorklund, D. M. (2022) · Biomolecules · doi:10.3390/biom12050600 · Cited by 52
“These proline-rich segments are also sites of Tau phosphorylation, and it was proposed that alteration of the normal proline isomerisation of Tau could lead to enhanced oligomerisation and an increased susceptibility to Alzheimer’s disease [80].”
BackgroundWu, M., Fang, K., Wang, W., Lin, W. J., Guo, L., & Wang, J. (2019) · Biophysics Reports · doi:10.1007/s41048-019-0086-2 · Cited by 44
Adams, L., Song, M. K., Yuen, S., Tanaka, Y., & Kim, Y. (2024) · Nature Aging · doi:10.1038/s43587-024-00583-6 · Cited by 68
FKBP5 and early life stress affect the hippocampus by an age-dependent mechanism
Criado‐Marrero, M., Smith, T. M., Gould, L. A., Kim, S., Penny, H. J., Sun, Z., Gulick, D., Dickey, C. A., & Blair, L. J. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100143 · Cited by 52
Self-citationELKAHLOUN, A. G., Hafko, R., & Saavedra, J. M. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0167-5 · Cited by 47
“There are 580 genes upregulated (red) and 1430 downregulated (blue) differentially expressed transcripts in hippocampus from Alzheimer's disease patients which are common to both GSE48350 and GSE1297 datasets.”
InfluentialTau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo
Gerson, J. E., Sengupta, U., & Kayed, R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6598-4_9 · Cited by 44
Self-citationBar‐Lavan, Y., Shemesh, N., Dror, S., Ofir, R., Yeger‐Lotem, E., & Ben‐Zvi, A. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006531 · Cited by 41
Hervás, R., & Oroz, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239186 · Cited by 46
“The removal of CHIP uncouples the proteasomal clearance of Hsp90 clients, leading ultimately to the aberrant aggregation of tau [92].”
BackgroundFujii, T., Ota, M., Hori, H., Hattori, K., Teraishi, T., Matsuo, J., Kinoshita, Y., Ishida, I., Nagashima, A., & Kunugi, H. (2014) · Scientific Reports · doi:10.1038/srep06696 · Cited by 46
Kumar, R., Moche, M., Winblad, B., & Pavlov, P. F. (2017) · Scientific Reports · doi:10.1038/s41598-017-14731-z · Cited by 40
Metadata
- Authors
- Blair, L. J., Nordhues, B. A., Hill, S. E., Scaglione, K. M., O’Leary, J. C., Fontaine, S. N., Breydo, L., Zhang, B., Li, P., Wang, L., Cotman, C., Paulson, H. L., Muschol, M., Uversky, V. N., Klengel, T., Binder, E. B., Kayed, R., Golde, T. E., Berchtold, N., & Dickey, C. A.
- Affiliations
- University of South Florida (US)
- University of Michigan (US)
- University of California, Irvine (US)
- Max Planck Institute of Psychiatry (DE)
- The University of Texas Medical Branch at Galveston (US)
- University of Florida (US)
- Corresponding author
- Wang, Li
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-09-03
- Volume
- 123
- Issue
- 10
- Pages
- 4158-4169
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3784538
- OpenAlex
- W2056613924
- Cited by
- 322
- References
- 72
- Citations by year
- 2026: 24 · 2025: 34 · 2024: 25 · 2023: 28 · 2022: 34 · 2021: 20 · 2020: 24 · 2019: 26 · 2018: 19 · 2017: 18 · 2016: 21 · 2015: 24 · 2014: 23 · 2013: 2
- FWCI
- 16.20
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- American Federation for Aging Research
- BrightFocus Foundation
- University of South Florida
- National Institutes of Health
- University of California, Irvine
- National Institute on Aging (P01AG000538, R01AG034667, P50AG016573)
- National Institute of Neurological Disorders and Stroke (K99NS073936, R00NS073936, R01NS073899, NS073899)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau protein, tau oligomerization, tau aggregation, tauopathy, Alzheimer's disease, FKBP51, HSP90, proteasome, tau clearance, amyloid fibril formation, neurotoxicity, tau transgenic mice
- MeSH terms
- Tacrolimus Binding Protein 5, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Gene Expression, Case-Control Studies, tau Proteins, Mice, Knockout, HSP90 Heat-Shock Proteins, DNA Methylation, Protein Structure, Quaternary, Tacrolimus Binding Proteins, Proteasome Endopeptidase Complex, Mice, Protein Multimerization, Young Adult, CA3 Region, Hippocampal, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.